Samsung finalizes Raypax beta siteKorean PACS firm Samsung has announced that Palo Alto Medical Clinic has agreed to be the beta site for the company’s Raypax PACS product. The clinic will be Samsung’s first U.S. installation of Raypax
Korean PACS firm Samsung has announced that Palo Alto Medical Clinic has agreed to be the beta site for the companys Raypax PACS product. The clinic will be Samsungs first U.S. installation of Raypax since it received 510(k) clearance earlier this year (
PNN
8/99). The system was installed the first week of August, and initially will deal with two modalities, CT and MRI. Samsung, which maintains U.S. operations in San Jose, CA, will work with PAMC to create a version of Raypax that meets the requirements of American radiologists, the company said.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.